3 results
This proof of concept study is to estimate the effect of SRCaBu (600 mg daily for four weeks) on compositional and functional characteristics of the microbiome for future sample size calculation.The secondary objectives: 1) To evaluate the short-…
Primary Objective1. To evaluate the efficacy of IMU-838 versus placebo as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy in progressive multiple sclerosis (PMS) patients with the Structural Image…
Primary:To compare the efficacy of asciminib versus Investigator selected TKI with respect to the proportion of patients that are in Major Molecular Response at Week 48. To compare the efficacy of asciminib versus Investigator selected TKI, within…